MG-S-2525

N/A

Report date: 2025/02/27 20:00:09

NMEFirst In Class

Base Information

Drug NameMG-S-2525

Drug Alias NameMG-S-2525

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSPS1/STE20-related protein kinase YSK4 inhibitors

TargetsSPS1/STE20-related protein kinase YSK4

Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsIdiopathic Pulmonary Fibrosis

ATC CodeN/A